Wuxi Biologics Release: Company Files for $300 Million Hong Kong IPO
Published: Jan 26, 2017
January 25, 2017 -- WuXi Biologics, the biologics arm of CRO/CMO WuXi AppTec, has filed to conduct its much-anticipated IPO on the Hong Kong Exchange. Trouble is, all the information about the transaction itself is redacted: there is no target for money raised, number of shares offered or timetable. Even the word "IPO" is carefully edited out of the document, leaving REDACTED in its place. Knowledgeable observers expect the IPO to take place in Q2, raise $300 million and value WuXi Biologics at $1.5 billion.